Single Antiplatelet Therapy Transition Tool for High Bleeding Risk
Patient and treatment details
Use this decision aid to support, not replace, individualized post-PCI antiplatelet review.
Clinical context
Dual antiplatelet therapy (DAPT) reduces recurrent atherothrombotic events after acute coronary syndrome (ACS), while increasing bleeding risk. The default duration and the appropriateness of an abbreviated strategy depend on ACS presentation, PCI features, ischemic risk, bleeding risk, drug tolerance, and clinical course.
How to use this decision aid
- Confirm high bleeding risk using a recognized framework such as ARC-HBR and review prior bleeding, anemia, renal function, age, and concomitant anticoagulation.
- Review PCI complexity, stent-related risk, recurrent ischemia, adherence, and the exact antiplatelet agent before making a change.
- For ACS patients who have tolerated ticagrelor-based DAPT, the 2025 ACC/AHA guideline recommends transition to ticagrelor monotherapy at least 1 month after PCI to reduce bleeding.
- For ACS patients undergoing PCI who are at high bleeding risk, transition to single antiplatelet therapy after 1 month may be reasonable. This is not an automatic rule for every patient or every agent.
- For ACS patients without high bleeding risk, DAPT for at least 12 months remains the default strategy unless individual circumstances warrant another approach.
Interpretation limits
This tool is a structured prompt for clinician review. It does not calculate ARC-HBR, estimate an individual patient's net clinical benefit, or determine which agent should be stopped. Evidence for early clopidogrel monotherapy after ACS is mixed; the drug choice requires clinical judgment.
References
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151:e771–e862.
doi:10.1161/CIR.00000000000013092023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44:3720–3826.
doi:10.1093/eurheartj/ehad191Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal. 2019;40:2632–2653.
doi:10.1093/eurheartj/ehz372Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.